Abstract-5-Hydroxytryptamine (5-HT)-induced arterial contraction depends on activation of the tyrosine kinasedependent extracellular signal-regulated mitogen-activated protein kinase (Erk MAPK) pathway. The importance of 5-HT in the control of peripheral resistance has been questioned because circulating free levels of 5-HT are low (in the nanomolar range). We tested the hypothesis that physiologically relevant concentrations of 5-HT potentiate arterial contraction in response to agonists proved to have importance in blood pressure maintenance (norepinephrine [NE] and endothelin-1 [ET-1]) in a tyrosine kinase-and an Erk MAPK-dependent manner. Strips of endothelium-denuded rat tail artery were used for the measurement of isometric force. The general tyrosine kinase inhibitor genistein (5 mol/L) and the inhibitor of MAPK/Erk kinase activation PD098059 (10 mol/L) shifted concentration-response curves to 5-HT (1ϫ10 Ϫ9 to 3ϫ10 Ϫ4 mol/L) rightward but did not shift concentration-response curves to NE or ET-1. In separate experiments, 5-HT (10 nmol/L) potentiated contraction in response to NE (20 nmol/L) by Ϸ200% to 300% and to ET-1 (0.3 and 1 nmol/L) by 640% and 180%, respectively. Genistein and PD098059 significantly (66% to 100%) reduced 5-HT-induced potentiation of both NE (20 nmol/L)-and ET-1 (0.3 and 1 nmol/L)-induced contraction. Thus, these data support the ability of low physiological concentrations of 5-HT to amplify arterial responses to hormones with bona fide effects on blood pressure in the novel manner of depending on a tyrosine kinase/Erk MAPK pathway. Although these findings were generated in large arteries, we speculate that they may be applicable to vascular functioning in the deoxycorticosterone acetate salt model of hypertension in which all 3 hormones, 5-HT, NE, and ET-1, have been implicated as causal factors. Key Words: norepinephrine Ⅲ endothelin Ⅲ protein kinases Ⅲ arteries Ⅲ hormones S ince its discovery in serum in 1948, 1 5-hydroxytryptamine (5-HT [serotonin]) has been of interest to the cardiovascular researcher. 5-HT has been implicated in numerous cardiovascular diseases; vascular reactivity to 5-HT is increased in arteries from animals with different forms of hypertension 2 and atherosclerosis. 3 However, it has been argued that 5-HT plays an insignificant role in the physiological control of blood vessel tone because uptake of 5-HT by platelets, adrenergic nerves, or both causes circulating levels of 5-HT to be low (estimated to be 15 to 120 nmol/L 4 ) and out of a range that can directly cause constriction. One manner by which physiological concentrations of 5-HT may exert an effect on vascular tone is through the potentiation of vascular contraction in response to other vasoactive substances.
S
ince its discovery in serum in 1948, 1 5-hydroxytryptamine (5-HT [serotonin]) has been of interest to the cardiovascular researcher. 5-HT has been implicated in numerous cardiovascular diseases; vascular reactivity to 5-HT is increased in arteries from animals with different forms of hypertension 2 and atherosclerosis. 3 However, it has been argued that 5-HT plays an insignificant role in the physiological control of blood vessel tone because uptake of 5-HT by platelets, adrenergic nerves, or both causes circulating levels of 5-HT to be low (estimated to be 15 to 120 nmol/L 4 ) and out of a range that can directly cause constriction. One manner by which physiological concentrations of 5-HT may exert an effect on vascular tone is through the potentiation of vascular contraction in response to other vasoactive substances.
5-HT-stimulated potentiation of agonist-induced contraction has classically been studied in the tail artery of the rat. [5] [6] [7] Norepinephrine (NE) was one of the first agonists established to be potentiated by 5-HT. The list of hormones of which contraction can be potentiated by 5-HT has grown and includes diverse agonists such as angiotensin II, vasopressin, prostaglandin F 2␣ , histamine, clonidine, ATP, 15-lipoxygenase, thromboxane A 2 , and diadenosine polyphosphates. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 5-HT-induced potentiation of agonist-induced contraction has also been observed in multiple vascular tissues, including the isolated perfused rat tail artery; rabbit femoral artery, ear artery, and aorta; human coronary artery; the perfused rat mesenteric bed; and mesangial cells. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] We tested the hypothesis that a physiologically relevant concentration of 5-HT (10 nmol/L) potentiates arterial contraction in response to agonists of proved importance in blood pressure maintenance (NE and endothelin-1 [ET-1]) and does so in a manner dependent on a signaling pathway inarguably important to vascular smooth muscle cell growth, the tyrosine kinase-dependent extracellular signal-regulated kinase mitogen-activated protein kinase (Erk MAPK) pathway. We and others recently established that this pathway not only is involved in 5-HT vascular smooth muscle cell mitogenesis 16 but also is 1 of the pathways used by the 5-HT 2A receptor to mediate arterial contraction in response to 5-HT. [17] [18] [19] Here we report the novel and important finding that the robust potentiation of NE-and ET-1-induced arterial contraction in the tail artery by 5-HT is significantly reduced by inhibitors of tyrosine kinases, including MAPK/Erk kinase (MEK), a tyrosine/threonine kinase crucial to functioning of the Erk MAPK pathway.
Methods
All experimental procedures were in accordance with institutional guidelines of Michigan State University.
Isolated Tissue Bath Protocol
Rats were euthanized (80 mg/kg pentobarbital IP), and the ventral tail artery was removed. Arteries were dissected into helical strips (1.0ϫ5 mm), and the endothelial cell layer was removed by rubbing the luminal side of the vessel with a moistened cotton swab. 
Protocol for Inhibition of Agonist-Induced Contraction by Inhibitors
Either vehicle (0.5% DMSO), general tyrosine kinase inhibitor genistein (5 mol/L), inhibitor of MEK activation PD098059 (10 mol/L), MEK inhibitor U0126 (50 mol/L), or 5-HT 2 receptor antagonist LY53857 (10 nmol/L) was added to the bath and incubated with tissues for 1 hour before the cumulative additions of 5-HT (1ϫ10
Ϫ8 mol/L). Only 1 curve was generated in each tissue.
Protocol for 5-HT/NE Potentiation Experiments
A 20 nmol/L concentration of NE was chosen in these experiments because tail artery strips responded with a similar contraction in response to repeated NE application and because this is a nearthreshold concentration of NE. Tissues were first administered NE (20 nmol/L) and washed for 20 minutes to allow arterial tone to return to baseline. Half of the tissues were then administered 5-HT (10 nmol/L) or the vehicle for 5-HT (water). This concentration of 5-HT was chosen because tissues respond with similar contraction in response to repeated application and this is a threshold concentration of 5-HT. Once contraction in response to 5-HT plateaued, NE was added. Tissues were washed for 20 minutes, and half of the tissues were administered a kinase inhibitor or the vehicle (0.5% DMSO) and allowed to incubate for 1 hour before the administration of 5-HT and then NE as described. In this way, tissues could serve as their own control. Thus, there were 4 experimental groups: 1 group challenged with NE in the absence of 5-HT and no kinase inhibitor; 1 group challenged with NE in the presence of 5-HT and no kinase inhibitor; 1 group challenged with NE, no 5-HT, and a kinase inhibitor; and the final group challenged with NE, 5-HT, and a kinase inhibitor. In some experiments, the 5-HT 2 receptor antagonist LY53857 (10 nmol/L) was added instead of a kinase inhibitor to examine the dependence of 5-HT-induced potentiation of NE-stimulated contraction on 5-HT receptor activation.
Protocol for 5-HT/ET-1 Potentiation Experiments
Because ET-1-induced contraction is so difficult to wash out, tissues could not be used as their own control as was done in the 5-HT/NE experiments. After a 1-hour incubation with either vehicle (0.5% DMSO) or inhibitor, the vehicle for 5-HT (water) or 5-HT (10 nmol/L) was added to the bath. When contraction in response to 5-HT plateaued, ET-1 was added cumulatively with a time period between the 3 concentrations tested (0.1, 0.3, and 1 nmol/L) to allow maximum contraction to be reached at each concentration. Thus, there were 4 experimental groups: 1 group challenged with ET-1 in the absence of 5-HT and no kinase inhibitor; 1 group challenged with ET-1 in the presence of 5-HT and no kinase inhibitor; 1 group challenged with ET-1, no 5-HT, and a kinase inhibitor; and the final group challenged with ET-1, 5-HT, and a kinase inhibitor.
Materials
Drug solutions were prepared fresh daily in water unless specified otherwise. Acetylcholine hydrochloride, 5-HT hydrochloride, NE hydrochloride, and phenylephrine hydrochloride were purchased from Sigma Chemical Co. ET-1 was purchased from Peninsula Laboratories Inc. U0126 (in DMSO) was from Promega. Genistein (in DMSO), LY53857, and PD098059 (in DMSO) were from Sigma/Research Biochemical International. Figure 1 demonstrates the effect of the general tyrosine kinase inhibitor genistein, inhibitor of MEK activation PD098059, and MEK inhibitor U0126 in reducing contraction in isolated rat tail arteries stimulated by 5-HT ( Figure  1A ), NE ( Figure 1B) , or ET-1 ( Figure 1C ). Inhibitors have previously been verified to reduce 5-HT-induced activation and tyrosyl-phosphorylation of the Erk MAPKs in aortic smooth muscle, 17, 19 and we published an examination in arteries, with the exception of U0126, of potential nonselectivities of these compounds. 17 At all 5-HT concentrations of Ն10 Ϫ8 mol/L, these inhibitors significantly reduced contraction in response to 5-HT. It is unlikely that these compounds are acting as 5-HT receptor antagonists because daidzein (5 mol/L), the structurally related but inactive isomer of genistein, was unable to shift 5-HT-induced contraction in rat tail artery. 17 In contrast, the same concentrations of genistein (5 mol/L) and PD098059 (10 mol/L) did not shift or reduce contraction in response to NE or ET-1 ( Figures 1B and  1C) . U0126 also did not reduce contraction in response to the low concentrations of NE and ET-1 used in the potentiation experiments but did significantly reduce the maximum contraction. In preliminary experiments, we have found that Activation of a tyrosine kinase-dependent/MEKdependent pathway by 5-HT to cause potentiation of both NE-and ET-1-induced contraction is supported by the finding that the same concentrations of genistein (5 mol/L) and PD098059 (10 mol/L), concentrations that did not alter contraction in response to NE and ET-1 alone, significantly reduced 5-HT-induced potentiation of both NE (Figure 2A )-and ET-1 ( Figure 2B )-induced arterial contraction.
Data Analyses

Results
Discussion
Arterial tone results from the summation of stimuli, both relaxant and contractile, within the smooth muscle. Many hormones and neurotransmitters can influence vascular smooth muscle tone, and they do not act singularly. Here we present evidence that the combination of 5-HT with either NE or ET-1 not only significantly potentiates vascular contraction in response to NE or ET-1 but also enables the potentiated contraction in response to NE and ET-1 to become dependent on a pathway that NE and ET-1 do not use to cause contraction individually in the tail artery, a tyrosine kinase/ Erk MAPK-dependent pathway. The finding that 5-HT can potentiate vascular contraction in response to NE is not new, 5-10 but few reports suggest that 5-HT can potentiate the effects of ET-1. 20 The importance of this report is to emphasize that the potentiation of arterial contraction in response to important vasoactive hormones can occur at physiologically relevant concentrations of 5-HT and that potentiation may allow a signal transduction pathway not normally used to mediate arterial contraction in response to NE and ET-1. It should be noted that these data were generated in the tail artery, an artery that is not a resistance artery. As such, whether these same events occur in true resistance arteries remains to be seen, and thus the conclusions we make with respect to the involvement of 5-HT-induced potentiation in control of total peripheral resistance must be considered speculative.
The receptors investigated in the tail artery have been characterized. The 5-HT receptor is of the 5-HT 2 receptor class 21 (supported by inhibition of 5-HT-induced contraction by the 5-HT 2 receptor antagonist LY53857), the ET-1 receptor is an ET A receptor, 22 and the ␣-adrenergic receptor is a mixture of ␣ 1 -and ␣ 2 -adrenergic receptors. 23, 24 All 3 classes of receptors activate similar, classic signaling pathways (plasma membrane calcium channels and phospholipase C), and all receptors have recently been identified as being able to activate the Erk MAPK pathway in vascular smooth muscle. Several investigators have demonstrated that Erk MAPK can phosphorylate caldesmon and, in doing so, release the calmodulin-mediated inhibition of actinomyosin ATPase and thereby promote smooth muscle contraction. [25] [26] [27] Whether a tyrosine kinase/Erk MAPK pathway-dependent pathway is used for arterial contraction appears to differ among receptors. For example, activation of the Erk MAPK pathway is important to vascular smooth muscle mitogenesis stimulated by 5-HT, 16 and 5-HT 2A receptor-mediated contraction is clearly tyrosine kinase/Erk MAPK dependent. [17] [18] [19] 28, 29 In contrast, the involvement of the tyrosine kinase or kinases/Erk MAPK pathway in ET-1-induced contraction is less clear. ET-1 acting at ET A receptors possesses the ability to activate the Erk MAPK pathway in human and rat vascular smooth muscle. 30, 31 Only a few reports demonstrate that ET-1-induced contraction can be blocked by tyrosine kinase inhibitors, 29 and although the MEK inhibitor PD098059 was able to reduce ET-1-induced contraction in the isolated rat uterus, 32 no reports specifically implicate the Erk MAPK pathway in arterial contraction in response to ET-1. Interestingly, the ability of ET-1 to act as a direct mitogen is not universally found in that some investigators report that ET-1 could activate the MAPK pathway in smooth muscle but was a poor mitogen. 31, 33 In vascular smooth muscle cells, NE has been reported to activate the Erk MAPK pathway, 34, 35 but the literature regarding the dependence of NE-induced contraction on tyrosine kinase or kinases or the Erk MAPK pathway is confusing.
Some reports demonstrate that NE-induced contraction can be blocked by tyrosine kinase inhibitors, 28, 36 whereas others, 37, 38 including the present study, suggest that NE/␣-adrenergic receptor-mediated contraction is not dependent on tyrosine kinase(s) or that high concentrations of the tyrphostin family of tyrosine kinase inhibitors and genistein are necessary to only slightly reduce NE-induced contraction. 39 These differences likely reflect the differences in species used (and hence, possible receptor subtype), the concentrations of tyrosine kinase inhibitors used, and the possibility that ␣-adrenergic receptors do not routinely use tyrosine kinases to mediate arterial contraction.
So why are these studies important, and what do the results mean? Activation of the Erk MAPK pathway is not the only mechanism mediating 5-HT-induced potentiation. Xiao and Rand 6 demonstrated in the isolated perfused rat tail artery that ketanserin and the L-type calcium channel antagonist diltiazem (10 mol/L) abolished 5-HT-mediated potentiation of NE-and phenylephrine-induced contraction. The 5-HT 2A receptor has long been associated with activation of calcium channels and phospholipase C, but we recently recognized that the Erk MAPK pathway is a third, parallel pathway of signaling that is used by arterial 5-HT 2A receptors. [17] [18] [19] Importantly, this study demonstrates that because 5-HT involves the Erk MAPK pathway in contraction, 5-HT enables contraction in response to NE and ET-1, more specifically, that potentiated by 5-HT, to become dependent on the tyrosine kinase/Erk MAPK pathway. The mechanism by which this occurs is unclear, and it is difficult to determine whether it is just 5-HT and its receptor interacting with the Erk MAPK pathway in the potentiated state or whether 5-HT provides NE and ET-1 with the opportunity to independently stimulate the Erk MAPK pathway.
We can speculate as to the importance of potentiation in the control of blood pressure. The finding that physiologically relevant concentrations of 5-HT can potentiate arterial contraction in response to low concentrations of hormones, NE and ET-1, with undisputed effects on total peripheral resistance suggests that this may occur in vivo and modulate not only contractility but possibly vascular smooth muscle growth as well. Does this mean that 5-HT is involved in the control of total peripheral resistance or the increased total peripheral resistance observed in hypertension? This is debatable. As many studies demonstrate that 5-HT receptor antagonists can reduce blood pressure in a hypertensive model 40 as do argue that 5-HT receptor antagonists are ineffective as antihypertensive agents 41 or that the reduction in blood pressure caused by 5-HT receptor antagonists such as ketanserin is due to nonselective blockade of ␣ 1 -adrenergic receptors. 42 This question remains intriguing, especially in light of the fact that NE, ET-1, and 5-HT have been implicated as causal factors in a model of hypertension that displays both increased peripheral vascular resistance and growth: the deoxycorticosterone acetate-salt hypertensive rat. 43, 44 In summary, we present evidence that a low, physiological concentration of 5-HT (10 nmol/L) can significantly potentiate rat tail artery contraction in response to NE and ET-1, and we present the novel finding that potentiation is dependent on activation of a tyrosine kinase/Erk MAPK pathway.
